MapLight Therapeutics, Inc. Segment Reporting Other Item Amount
MapLight Therapeutics, Inc. (MPLT) reported Segment Reporting Other Item Amount of -$3.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentReportingOtherItemAmount · last filed 2026-08-13
- MapLight Therapeutics, Inc. segment reporting other item amount for the quarter ending 2026-06-30 was -$3.36M.
- MapLight Therapeutics, Inc. segment reporting other item amount for the quarter ending 2026-03-31 was -$3.83M.
- MapLight Therapeutics, Inc. segment reporting other item amount for the quarter ending 2025-12-31 was -$3.83M.
- MapLight Therapeutics, Inc. segment reporting other item amount for the quarter ending 2025-09-30 was -$2.08M.
- MapLight Therapeutics, Inc. segment reporting other item amount for fiscal 2025 was -$7.93M.
- MapLight Therapeutics, Inc. segment reporting other item amount for fiscal 2024 was -$5.37M.
| Period end | Segment Reporting Other Item Amount 3 month | Segment Reporting Other Item Amount 6 month | Segment Reporting Other Item Amount 9 month | Segment Reporting Other Item Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.36M 10-Q · filed 2026-08-13 | -$7.19M 10-Q · filed 2026-08-13 | -$11.02M derived: sum of 3 quarters · filed 2026-08-13 | -$13.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$3.83M 10-Q · filed 2026-05-14 | -$7.66M derived: sum of 2 quarters · filed 2026-05-14 | -$9.74M derived: sum of 3 quarters · filed 2026-05-14 | -$10.56M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$3.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$5.91M derived: sum of 2 quarters · filed 2026-03-26 | -$6.73M derived: sum of 3 quarters · filed 2026-08-13 | -$7.93M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$2.08M 10-Q · filed 2025-12-04 | -$2.90M derived: sum of 2 quarters · filed 2026-08-13 | -$4.10M 10-Q · filed 2025-12-04 | -$5.65M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$818.00K 10-Q · filed 2026-08-13 | -$2.02M 10-Q · filed 2026-08-13 | -$3.57M derived: sum of 3 quarters · filed 2026-08-13 | -$5.45M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$1.20M 10-Q · filed 2026-05-14 | -$2.75M derived: sum of 2 quarters · filed 2026-05-14 | -$4.63M derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$3.43M derived: sum of 2 quarters · filed 2026-03-26 | -$5.37M 10-K · filed 2026-03-26 | |
| 2024-09-30 | -$1.88M 10-Q · filed 2025-12-04 | -$3.82M 10-Q · filed 2025-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |